



Fe-S Proteins in Health and Disease

Guest Editor:

Dr. Marie-Pierre Golinelli-Cohen

Institut de Chimie des
Substances Naturelles, CNRS
Centre National de la Recherche
Scientifique, Gif-sur-Yvette,
France

Deadline for manuscript
submissions:

closed (31 July 2021)

Message from the Guest Editor

Dear Colleagues,

Iron-sulfur (Fe-S) clusters are ubiquitous redox active prosthetic groups typically involved in electron transfer (e.g., mitochondrial respiration) in essential cellular processes. However, Fe-S proteins were recently found in most of the eukaryotic organelles supporting diverse and unexpected functions (e.g., DNA polymerases and repair, transcriptional regulators). Because of the essential cellular roles played by Fe-S proteins, defects in either Fe-S proteins or the biogenesis/repair of their cluster lead to several human diseases, including neurologic dysfunction, cancer and diabetes.

We cordially invite authors in the field to submit original research or review articles highlighting the implications of Fe-S proteins in diseases and human health, including the development of drugs targeting Fe-S proteins.

Dr. Marie-Pierre Golinelli-Cohen

Guest Editor





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research
Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA
2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

High Visibility: indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [CAPUS / SciFinder](#), and [other databases](#).

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Contact Us

Biomedicines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
[X@Biomed_MDPI](#)